贝凡洛尔(Bevantolol,简称BEV)是一种新的具特殊药理作用的心脏选择性β阻滞剂。本文采用随机双盲安慰剂对照试验比较了BEV与阿替洛尔治疗慢性稳定型心绞痛的效果。方法:39例稳定型劳力性心绞痛病人。研究前停用一切心血管药物。所有病人在用安慰剂治疗2周后,随机口服BEV(20例)200mg,每日1次或阿替洛尔(ATE,19例),50mg,每日1次。给予上述药物4周后,若运动时间的改善不足20％,则剂量加倍再用4周;否则,继续维持原剂量4周。给予安慰 Bevantolol (BEV) is a new cardioselective beta-blocker with specific pharmacological effects. This randomized double-blind placebo-controlled trial compared the efficacy of BEV and atenolol in the treatment of chronic stable angina. Methods: 39 patients with stable angina pectoris. Stop using all cardiovascular drugs before the study. All patients were randomized to BEV (20) 200 mg once daily or atenolol (ATE, 19), 50 mg once daily for 2 weeks after placebo treatment. Four weeks after giving the above drug, if the improvement of exercise time is less than 20%, the dosage is doubled for another 4 weeks; otherwise, the original dosage is continued for 4 weeks. Give comfort